Innate Pharma : Perfectly financed to reach its catalysts in the short term
>Financial visibility out to end-2025 - Innate Pharma reported this morning its sales and cash position for the last 9M. Sales totalled € 10.2m (vs € 36.5m in 2023) resulting from the recognition of payments received as part of its partnerships with AstraZeneca and Sanofi.The cash position at end-September came to € 96.4m, which should enable it to finance its businesses out to end-2025. Bear in mind that the company has an equity financing line (at-the-market) ...Innate Pharma S.A. is a biopharmaceutical Company developing immunotherapy drugs for cancer and inflammatory diseases. Co. specializes in the development of new monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Also, Co. has three product-candidates resulting from its research platform are being tested in clinical trials; two of these by Co.'s partners, Bristol-Myers Squibb and Novo Nordisk A/S. Co. focuses on immunopharmacology and antibody technology. Co. has a panel of molecular and cellular assays and in vivo models for assessing the pharmacodynamics, the pharmacotoxicology and efficacy of drug candidates.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.